| Filed On | Filing |
|---|---|
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Company Drives Significant Increases in Test Volume and Ordering Providers with Florida Becoming Second Medicaid State Covering Test |
| 13 Oct 2026 |
Form 4: Inglis Tiffany Eul Davis, Chief Medical Officer
Sold 8,024 shares ($16.3K) |
| 13 Oct 2026 | 144 |
| 11 Sep 2026 |
Form 4: Anderson Dyaarl Lee Jr., Chief Commercial Officer
Sold 1,800 shares ($3.6K) |
| 11 Sep 2026 |
Form 4: Lindgardt Zhenya, Director
Sold 7,022 shares ($14K) |
| 11 Sep 2026 |
Form 4: Inglis Tiffany Eul Davis, Chief Medical Officer
Sold 486 shares ($972) |
| 11 Sep 2026 |
Form 4: Jackson Benjamin, General Counsel
Sold 2,190 shares ($4.38K) |
| 11 Sep 2026 | 144 |
| 11 Sep 2026 | 144 |
| 11 Sep 2026 | 144 |
| 11 Sep 2026 | 144 |
| 11 Sep 2026 | 144 |
| 09 Sep 2026 |
Form 4: Lindgardt Zhenya, Director
Sold 20,139 shares ($40.3K) |
| 09 Sep 2026 | 144 |
| 09 Sep 2026 | 144 |
| 02 Sep 2026 | Form 4: Aerts Austin, Chief Financial Officer |
| 01 Sep 2026 |
Form 4: Gleason Scott, Chief Financial Officer
Received 117,924 shares as a grant or award · Granted 169,624 Stock Option (right to buy) |
| 01 Sep 2026 |
Form 3: Gleason Scott, Chief Financial Officer
No securities owned |
| 19 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This Employment Agreement (this “Agreement”) is effective for all purposes as of August 14, 2026 (the “Effective Date”), by and between Sera Prognostics, Inc., a Delaware corporation (the “Company”), and Scott Gleason (the “Employee”). |
Loading...